GLP-1 Plan Switch: Keep Your Prescription Through Open Enrollment

A GLP-1 plan switch during open enrollment is not automatic. Prior authorization doesn't transfer between insurers, coverage gaps are common between November enrollment and a January 1 effective date, and some employers changed their GLP-1 benefit structures for 2027 plan years. Here's exactly what happens during a GLP-1 plan switch and how to keep semaglutide or tirzepatide going through the transition.

By Alexandru Vieru | Independently researched | Published October 2026. Insurance and coverage data verified: September 2026.

⚠️ Compounded semaglutide and tirzepatide are not FDA-approved drugs. They are custom preparations from licensed compounding pharmacies, legally distinct from brand-name Wegovy and Zepbound. Insurance does not reimburse compounded medications. Speak with your prescriber before any changes to your GLP-1 therapy.

GLP-1 Plan Switch: What Actually Happens on January 1?

The short answer: more than most people expect, and the disruption is front-loaded.

When your new insurance plan takes effect on January 1, the following reset simultaneously:

The coverage gap problem: Most open enrollment periods (employer OEP and ACA Marketplace) run October–November, but new coverage doesn't start until January 1. If your current plan approved Wegovy for 2026, that approval ends December 31. Your new insurer's approval, even if you filed the PA in November, may not be processed by January 1. That gap is where most prescriptions stall. (The exception: a qualifying life event like a job change or marriage triggers a Special Enrollment Period that lets you switch plans mid-year with a different timeline.)

Prior Authorization Doesn't Transfer in a GLP-1 Plan Switch

Prior authorization for GLP-1 medications is more demanding than for most drugs. Insurers typically require:

• BMI documentation: Usually BMI ≥30, or BMI ≥27 with at least one qualifying comorbidity (hypertension, prediabetes, type 2 diabetes, dyslipidemia, sleep apnea, PCOS, or established cardiovascular disease).
• Provider attestation: A letter from your prescribing clinician documenting medical necessity.
• Failed alternative documentation: Many plans still require evidence that you tried a lower-cost behavioral program or lower-tier medication first.
• Lab work: Some plans require recent HbA1c or lipid panel results.

When you make a GLP-1 plan switch, none of your 2026 PA documentation automatically transfers. Your new insurer has no obligation to honor another company's coverage decision. You are, administratively, starting from zero. Even if you have been on semaglutide for eight months and are mid-titration.

This is not a flaw in the system. Each insurer is pricing risk on their own formulary, their own network, and their own step-therapy logic. But it means the practical window to file your new PA during a GLP-1 plan switch is before December 31. Not after January 1, when you've already run out of medication.

Brand-Name vs. Compounded GLP-1 During a Plan Switch

How much this disrupts you depends largely on which type of GLP-1 you are currently using.

If you use brand-name Wegovy or Zepbound: Your coverage stops completely when your old plan year ends. You either have a new PA approved and active under your new plan on January 1, or you pay the manufacturer's self-pay price: $349 a month for the Wegovy pen through NovoCare (novocare.com), or $299 to $449 for Zepbound through LillyDirect (lilly.com) (checked 26 October 2026). That is a real cost for a one or two month gap, so plan the bridge before the plan year ends.

If you use compounded semaglutide or tirzepatide from a telehealth clinic: Your prescription is already outside the insurance system. Your compounding pharmacy and telehealth provider relationship is unaffected by your plan change. There is no January 1 disruption to your supply. The cost stays the same: currently $49–$199 per month depending on the clinic and medication format.

This is the single most underappreciated advantage of compounded GLP-1 during plan transitions: continuity of supply is not tied to your insurer's PA calendar. You can keep titrating on the same schedule while your new insurer processes your PA for brand-name medication in the background. If you choose to pursue brand-name coverage at all.

For a full cost comparison of compounded versus brand-name options, see our compounded vs. brand semaglutide guide.

Should You Stockpile Medication Before Your Plan Changes?

A common question. And the honest answer is nuanced.

For brand-name Wegovy or Zepbound: Some plans allow a 90-day supply. If your pharmacy benefit allows it and you have PA approved before year-end, filling a 90-day supply in December creates a buffer that carries you through a January PA gap. Check whether your current plan permits a 90-day fill and whether your pharmacy participates.

For compounded semaglutide: There is no reason to stockpile. Your supply chain does not depend on your insurance. Compounding pharmacies do not require insurance approval. You can order your next vial or pen on your normal refill schedule regardless of what happens with your insurance.

The more important "stocking up" question: Make sure your prescription is renewed before December 31. Many telehealth GLP-1 clinics require a check-in visit to renew a prescription annually or bi-annually. If your renewal falls in January, schedule it in November or early December instead, so you do not lose access to your prescription and lose insurance coverage at the same time.

Top picks for uninterrupted cash-pay GLP-1: Wellorithm offers both compounded GLP-1 and brand-name Wegovy, Ozempic, Zepbound, and Mounjaro on one account. That is useful if your new plan ends up covering brand-name medication and you want a single provider for both phases. Rated 7.9/10, starting at $247/mo after a $147 first month compounded. Read our Wellorithm review →

How to Restart Prior Authorization With Your New Plan

If you are on brand-name GLP-1 medication and switching to a plan that covers it, move fast. PA decisions can take 7–21 business days depending on the insurer, and urgent reviews are typically reserved for truly acute situations. Weight-loss GLP-1 rarely qualifies for expedited review.

Step-by-step PA restart process:

1. Get your new plan documents in October. Before you finalize your enrollment, download the 2027 formulary and look up your GLP-1 medication. Verify it is on formulary and confirm which tier and PA requirements apply.
2. Alert your prescriber in November. Give your clinician at least six weeks before January 1 to prepare new PA documentation. They need the new insurer's name, your new group number, and the PA form (usually on the insurer's provider portal).
3. File PA in mid-November. This gives enough time for one resubmission if the initial request is denied or needs additional documentation.
4. Request a peer-to-peer review if denied. If your insurer denies your PA, your prescriber can request a direct call with the insurance medical reviewer. This is standard practice and overturns a significant portion of initial denials.
5. Have a cash-pay backup. If your January 1 date arrives without an active PA, have a cash-pay compounded option in place. You can switch back to brand-name coverage the moment your new PA is approved.

Employer Plans That Changed GLP-1 Coverage in 2026: What to Watch For

The employer GLP-1 coverage landscape shifted again in 2026. After years of adding GLP-1 benefits under pressure from employees and health coaches, a meaningful number of large employers pulled back. Either limiting coverage to CVD-indicated patients (following the Medicare model) or capping the duration to 24 months.

If your employer plan has changed, look specifically for:

• Indication creep-backs: Plans that previously covered GLP-1 for "obesity management" that now require documented CVD or type 2 diabetes, following CMS guidance.
• Duration limits: Annual maximums (common: 12–24 months of coverage lifetime) that may apply if you've been on medication since 2024 or 2025.
• Step therapy reinstatement: Plans that paused step-therapy requirements (trying lower-cost options first) during the shortage period have started reinstating them now that shortage designations have ended.
• Pharmacy benefit carve-outs: Some employers now manage GLP-1 coverage through a separate specialty pharmacy benefit manager (PBM). Your current specialty pharmacy may not be in that network.

None of this means GLP-1 is uncoverable. It means the criteria have tightened. If your 2026 coverage was grandfathered under less strict rules, your 2027 PA may face a higher bar even with the same insurer.

The Cash-Pay Bridge Strategy: Compounded GLP-1 During a Plan Switch

For the 30–60 day window between your old coverage ending and your new PA taking effect, compounded telehealth GLP-1 is the most common bridge strategy.

The math is straightforward: one month of cash-pay compounded semaglutide ($49–$199 depending on the clinic) costs less than one month of the brand-name Wegovy pen self-pay ($349/month through NovoCare (novocare.com), checked 26 October 2026). Unless you have compelling reason to pause medication entirely, bridging on compounded is nearly always the lower-risk clinical and financial choice. Provided you use a vetted clinic with physician oversight.

Wellorithm offers both compounded and brand-name treatments. Confirm whether it accepts your new insurance and how a medication change would be handled before planning a transition. Welludr's monthly plan has no annual commitment. Both are in the partner list below, in order of our score:

See our full cheapest GLP-1 options for the current ranked list.

When Compounded GLP-1 Is the Right Move After a Plan Switch

Not every GLP-1 plan switch ends with a plan that covers GLP-1. If your 2027 employer plan eliminated the benefit or your marketplace plan doesn't list Wegovy or Zepbound on formulary, cash-pay compounded medication is not a consolation prize. It is a deliberate choice that many patients prefer for reasons beyond cost:

• No prior authorization cycle: Every PA approval is temporary. When your conditions change, your dose changes, or your plan has turnover, PA can be denied. Cash-pay compounded has no approval to lose.
• Wider medication options: Most insurers cover only brand-name Wegovy (semaglutide) or Zepbound (tirzepatide), not both, and rarely in oral formulations. Telehealth clinics in our ranking offer semaglutide, tirzepatide, oral options, and combination protocols.
• Pricing predictability: Your monthly cost does not change based on your deductible reset, tier changes, or formulary updates. What you pay in January is what you pay in December.

For an unbiased look at when insurance coverage is worth pursuing versus when cash-pay makes more financial sense, see our open enrollment decision guide and our GLP-1 insurance coverage overview.

What to Do Right Now (October 2026 Action Checklist)

The open enrollment window feels administrative, but for patients mid-titration on GLP-1 medication, the January 1 transition is the riskiest moment in the calendar year. The clinics and the medication are not going anywhere. The only thing that changes is who is paying for it, and how smoothly that handoff goes is almost entirely a function of how far in advance you plan.

---

Top picks for cash-pay GLP-1 during plan transitions:

• Wellorithm review
• Gala Health review
• Welludr review

Related reading:

• GLP-1 Open Enrollment 2026: Switch Plans or Cash Pay?
• Medicare GLP-1 Bridge Program 2026: $50/Mo Wegovy & Zepbound
• Compounded vs. Brand-Name GLP-1: The Full Cost Breakdown
• Cheapest Semaglutide Online in 2026 (All-In Prices)
• How to Avoid GLP-1 Scams

---

Affiliate disclosure: MyGLP1 Guides earns a commission when you click to visit a clinic and enroll. Scores remain evidence-based; active partners are listed first at equal displayed scores. See our editorial policy and affiliate disclosure for details.

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and supervision by a licensed healthcare provider. Compounded semaglutide and tirzepatide are not FDA-approved drugs.